These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 16047204)

  • 21. Prophylactic use of myelopoietic growth factors in children after myelosuppressive and myeloablative therapy.
    Satwani P; Bessmertny O; Morris E; Cairo MS
    Curr Hematol Rep; 2003 Nov; 2(6):480-90. PubMed ID: 14561392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.
    Crawford J; Dale DC; Lyman GH
    Cancer; 2004 Jan; 100(2):228-37. PubMed ID: 14716755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors.
    Timmer-Bonte JN; Tjan-Heijnen VC
    Anticancer Drugs; 2006 Sep; 17(8):881-9. PubMed ID: 16940798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
    Ghalaut PS; Sen R; Dixit G
    J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review of the value of colony stimulating factors for prophylaxis of febrile neutropenic episodes in adult patients treated for haematological malignancies.
    Levenga TH; Timmer-Bonte JN
    Br J Haematol; 2007 Jul; 138(2):146-52. PubMed ID: 17593021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Granulocyte colony-stimulating factors: finding the right indication.
    Lyman GH; Shayne M
    Curr Opin Oncol; 2007 Jul; 19(4):299-307. PubMed ID: 17545791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Colony-stimulating factors as an adjunct to chemotherapy in small cell lung cancer.
    Urban T; Schuller MP; Lebeau B
    Eur Respir J; 1996 Mar; 9(3):596-602. PubMed ID: 8730024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?
    Klastersky J; Awada A; Aoun M; Paesmans M
    Curr Opin Oncol; 2009 Jul; 21(4):297-302. PubMed ID: 19509500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment: Implications for oncology nurses.
    Kearney N; Friese C
    Eur J Oncol Nurs; 2008 Feb; 12(1):14-25. PubMed ID: 18291720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing the management of chemotherapy-induced neutropenia.
    Dale DC
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):679-84. PubMed ID: 16258470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC).
    Grossi F; Tiseo M
    Crit Rev Oncol Hematol; 2006 Jun; 58(3):221-30. PubMed ID: 16697211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The colony-stimulating factors: use to prevent and treat neutropenia and its complications.
    Komrokji RS; Lyman GH
    Expert Opin Biol Ther; 2004 Dec; 4(12):1897-910. PubMed ID: 15571452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myeloid growth factors.
    Crawford J; Allen J; Armitage J; Blayney DW; Cataland SR; Heaney ML; Htoy S; Hudock S; Kloth DD; Kuter DJ; Lyman GH; McMahon B; Steensma DP; Vadhan-Raj S; Westervelt P; Westmoreland M;
    J Natl Compr Canc Netw; 2011 Aug; 9(8):914-32. PubMed ID: 21900221
    [No Abstract]   [Full Text] [Related]  

  • 34. Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel.
    Gridelli C; Aapro MS; Barni S; Beretta GD; Colucci G; Daniele B; Del Mastro L; Di Maio M; De Petris L; Perrone F; Thatcher N; De Marinis F
    Crit Rev Oncol Hematol; 2007 Jul; 63(1):53-64. PubMed ID: 17368037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of decision analysis to evaluate the costs and benefits of filgrastim (G-CSF) therapy.
    Peroutka JA; Mutnick AH
    Formulary; 1995 Jul; 30(7):394-5, 400-4. PubMed ID: 10151731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Granulocytic growth factors and cancer-related neutropenia: limited effects.
    Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical applications of colony-stimulating factors.
    Groopman JE
    Semin Oncol; 1988 Dec; 15(6 Suppl 6):27-33. PubMed ID: 2462748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Granulocyte and granulocyte macrophage colony-stimulating factors as therapy in human and veterinary medicine.
    Fernández-Varón E; Villamayor L
    Vet J; 2007 Jul; 174(1):33-41. PubMed ID: 17029990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and other immunomodulatory therapies for the treatment of infectious diseases in solid organ transplant recipients.
    Page AV; Liles WC
    Curr Opin Organ Transplant; 2008 Dec; 13(6):575-80. PubMed ID: 19060545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Use of colony-stimulating factors as possible therapeutic agents].
    Testa U
    Ann Ist Super Sanita; 1989; 25(2):363-7. PubMed ID: 2511793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.